Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab

被引：0
|
作者：
Van Asten, K. [1 ]
Jongen, L. [1 ]
Beuselinck, B. [2 ]
Laenen, A. [3 ]
Wildiers, H. [2 ]
Poppe, A. [4 ]
Floriss, G. [5 ]
Christiaens, M. [6 ]
Neven, P. [4 ]
机构：
[1] Katholieke Univ Leuven, Oncol, Leuven, Belgium
[2] UZ Leuven, Gen Med Oncol, Leuven, Belgium
[3] Katholieke Univ Leuven, Interuniv Ctr Biostat & Stat Bioinformat, Leuven, Belgium
[4] UZ Leuven, Gynaecol & Obstet, Leuven, Belgium
[5] UZ Leuven, Imaging & Pathol, Leuven, Belgium
[6] UZ Leuven, Surg, Leuven, Belgium
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P270
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [21] Outcome of non-metastatic HER2 positive breast cancer
    Mehmood, T.
    Rashid, A.
    Irfan, N.
    Hameed, S.
    Shah, M. Ali
    Jamshed, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S54 - S54
  • [22] TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER
    Heng, Sharon
    Pokharel, Khageshwor
    Gilbar, Peter
    Tannock, Margot
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 153 - 153
  • [23] Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer
    Bulut, Nilufer
    Harputluoglu, Hakan
    Dizdar, Omer
    Altundag, Kadri
    JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (02) : 241 - 241
  • [24] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [25] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    Lluch-Gomez, J.
    Nunez-Alvarez, V.
    de la Torre-Hita, C.
    Bernal-Gomez, M.
    Campini-Bermejo, A.
    Perdomo-Zaldivar, E.
    Rodriguez-Perez, L.
    Calvete-Candenas, J.
    Martinez-Bautista, M. J.
    Benitez-Rodriguez, E.
    Baena-Canada, J. M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [26] TRASTUZUMAB EMTANSINE FOR HER2 POSITIVE BREAST CANCER PATIENTS: AN UPDATED SYSTEMATIC REVIEW
    Valle, P. M.
    Mosegui, G. B.
    Vianna, C. M.
    Araujo, R. L.
    Felicissimo, T.
    Lima, I. J.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A816
  • [27] Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options
    Bae, Sangmee
    Hurvitz, Sara
    CURRENT CANCER THERAPY REVIEWS, 2015, 11 (04) : 269 - 291
  • [28] Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Laura Díaz-Gil
    Fara Brasó-Maristany
    Claudriana Locatelli
    Ariana Centa
    Balász Győrffy
    Alberto Ocaña
    Aleix Prat
    Atanasio Pandiella
    Journal of Experimental & Clinical Cancer Research, 40
  • [29] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    J. Lluch-Gómez
    V. Núñez-Álvarez
    C. de la Torre-Hita
    M. Bernal-Gómez
    A. Campini-Bermejo
    E. Perdomo-Zaldívar
    L. Rodríguez-Pérez
    J. Calvete-Candenas
    M. J. Martínez-Bautista
    E. Benítez-Rodríguez
    J. M. Baena-Cañada
    Scientific Reports, 13
  • [30] Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer
    Nilufer Bulut
    Hakan Harputluoglu
    Omer Dizdar
    Kadri Altundag
    Journal of Neuro-Oncology, 2008, 86 : 241 - 241
12345